Bone related events (SREs) such as bone pain, pathological fractures, spinal cord compression, and hypercalcemia due to bone metastases from breast cancer can cause patients extreme pain and seriously affect their quality of life. Therefore, the treatment of bone metastases is of great importance. Breast cancer bone metastasis diagnosis 1.ECT can be used as the initial screening test for breast cancer bone metastasis; X-ray, CT and MRI are the imaging confirmatory tests for bone metastasis. For patients with abnormal bone ECT scan, the above tests should be performed to confirm the bone metastasis; PET-CT and biochemical index of bone metabolism cannot be the routine diagnostic methods at present. MRI scan is highly sensitive to diagnose bone metastasis, and MRI of the spine can clarify whether there is bone destruction and understand the stability of the spine. The typical signal of breast cancer spine metastasis: abnormal signal distribution and intensity of the affected vertebral body and pelvis are not uniform, equal or low signal in T1WI, high signal or mixed high signal in T2WI. The use of bisphosphonates for breast cancer bone metastases: First generation: clodronate 1600 mg/day, orally; clodronate injection 300 mg/day, intravenously for >2 hours, after 5 consecutive days, change to oral formulation; Second generation: pamidronate 90 mg, intravenously for >2 hours, repeated every 3-4 weeks; Third generation: zoledronic acid 4 mg, intravenously for >15 minutes, repeated every 3-4 weeks minutes, repeated every 3-4 weeks; ibandronic acid 6 mg, intravenous, repeated every 3-4 weeks. Use of bisphosphonates and precautions 1. Bisphosphonates are not currently recommended for the prevention of bone metastases in patients without imaging evidence of bone metastases and in patients who present with extraosseous metastases but no evidence of bone metastases. For patients with breast cancer bone metastases with expected survival ≥ 3 months and creatinine < 3,0 mg/dl, zoledronic acid or pamidronate disodium should be added to the regimen of conventional chemotherapy and endocrine therapy against bone destruction, especially in patients with osteolytic and/or weight-bearing bone metastases (Class I recommendation). 3. Bisphosphonates can be used in combination with radiotherapy, chemotherapy, endocrine therapy, and analgesics. Studies have shown that bisphosphonates may cause osteonecrosis of the jaw (incidence about 5.48%), avoid dental operations and pay attention to oral hygiene during treatment. 5.No studies have shown that bisphosphonates have an effect on overall survival. 6. Calcium and vitamin D should be supplemented with a daily dose of 1200-1500 mg of calcium and 400-800 IU of vitamin D3 while taking bisphosphonates. 7. The current study data support a 2-year treatment duration for bisphosphonates.